ClinicalTrials.gg
Not yet recruitingNCT07664124Acti-nRollUpdated Jun 23, 2026

Digital Monitoring of Upper Limb Function in Non-Ambulant DMD

An interventional study of Performance of the Upper Limb (PUL) Test and Brook test in Duchenne Muscular Dystrophy (DMD), sponsored by Centre Hospitalier Universitaire de Liege. Not yet recruiting at 1 site in Belgium. Open to male participants. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Centre Hospitalier Universitaire de Liege · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium — 14 open to participants now, 20 under way, 6 of them phase 3. Muscular Dystrophy, Duchenne · Belgium.

Planned enrollment
36th of 52
50 · median 90
Started
2026
with 2 others
No phase
4 of 56
3 open now
Primary completion
2029-06
later than 13 of 19 live
Registered
56th of 56
by date
Lead sponsor
3 of 56
Centre Hospitalier Universitaire de Liege

Among the 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium, this one is the 36th largest by planned enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 with no phase, reaches primary completion later than 13 of the 19 other live ones, and was the 56th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

14 of the 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium, or all of them as a file.
02

Study summary

Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder caused by the absence of dystrophin, leading to progressive muscle degeneration. Symptoms typically begin in early childhood and result in loss of ambulation by early adolescence, followed by cardiorespiratory complications. Although early treatment, including corticosteroids and emerging therapies, can slow disease progression, sensitive tools to monitor functional decline-particularly in non-ambulant patients-remain limited.

Current assessments rely primarily on clinical scales and hospital-based evaluations, which may not detect subtle changes or reflect real-life function. Digital outcome measures derived from wearable sensors offer a promising approach for continuous, objective monitoring in daily life. This study aims to evaluate the feasibility, reliability, clinical validity, and sensitivity of digital measures to assess upper limb function in non-ambulant patients with genetically confirmed DMD. The Syde device, previously validated in ambulant DMD patients, will be investigated for its applicability in this population.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)

Keywords

  • Non-ambulant
  • digital endpoint
  • upper limb
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with genetically confirmed Duchenne Muscular Dystrophy (DMD).
  • Non-ambulant at the time of inclusion (not able to walk 10m without external aid).
  • A legal guardian willing and able to provide written for participation in the study if \< 18 years old.

Exclusion criteria

Exclusion Criteria:

  • Any acute or chronic condition that, in the opinion of the investigator, may significantly interfere with the assessments and/or motor function progression.
  • Participation in an interventional clinical trial.
  • No access to internet connection or alternatively no capacity to come on-site to bring the Syde every 6 months after the recording periods for data retrieval by Liège team
  • Scoliosis surgery within the previous 6 months or planned within the next year
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Non-ambulant participants with Duchenne Muscular Dystrophy (DMD)

    Diagnostic Test: Performance of the Upper Limb (PUL) Test · Diagnostic Test: Brook test · Diagnostic Test: Dynamometric measurements of muscle strength · Diagnostic Test: Forced Vital Capacity (FVC) test · Diagnostic Test: Clinical Global Impression - Severity (CGI-S) · Diagnostic Test: Clinical Global Impression - Improvement (CGI-C) · Other: Patient Global Impression of severity (PGI-S) · Device: Syde

Interventions

  • Diagnostic testPerformance of the Upper Limb (PUL) Test

    This test consists of a set of small manoeuvres (lifting a box, writing, etc.) designed to evaluate the upper-limb functionality of non-ambulatory patients. It was developed specifically for use in cases of Duchenne muscular dystrophy.

  • Diagnostic testBrook test

    The Brooke Upper Extremity Functional Rating Scale will be used to assess the global functional level of upper limb involvement. This 6-point ordinal scale classifies patients according to their highest achievable upper limb function, from full arm abduction to absence of useful hand function.

  • Diagnostic testDynamometric measurements of muscle strength

    Dynamometric measurements of the maximum force of the following functions will be taken with the MyoTools: palmar grip (MyoGrip) and thumb-index pinch (MyoPinch). Test will be realized on the dominant side. Patients will be encouraged during the test. They will be given three trials and the best score will be entered.

  • Diagnostic testForced Vital Capacity (FVC) test

    Forced Vital Capacity (FVC) will be assessed using standardized spirometry procedures. The primary parameter will be FVC expressed as percentage of predicted values. At least three acceptable and reproducible maneuvers will be performed according to standard guidelines.

  • Diagnostic testClinical Global Impression - Severity (CGI-S)

    The CGI-S is a clinician-rated scale used at baseline to assess the overall severity of the participant's condition, based on all available clinical information. The rating reflects the clinician's judgment without standardized scoring rules and must be performed by a clinician experienced in Duchenne Muscular Dystrophy. The CGI-S evaluates three domains: physical motor function, respiratory function, and bulbar function. It is completed after all other study assessments (excluding patient-reported outcomes) to ensure a comprehensive evaluation.

  • Diagnostic testClinical Global Impression - Improvement (CGI-C)

    The CGI-C is used at each follow-up visit to assess changes in the participant's condition relative to baseline. It provides a clinician-determined measure of improvement or worsening, based on overall clinical judgment rather than fixed criteria. Like the CGI-S, it covers physical motor, respiratory, and bulbar domains and is performed after all other study assessments (excluding patient-reported outcomes). The CGI-C is expected to track consistently with prior CGI-S evaluations, reflecting changes in disease status over time.

  • OtherPatient Global Impression of severity (PGI-S)

    The PGI-S (Patient Global Impression of Severity) is a simple, validated, single-item self-administered scale used to assess the current severity of a patient's condition. Widely used in clinical trials, it allows patients to rate their condition, on a 4- to 6-point scale (from 'Normal' to 'Very severe').

  • DeviceSyde

    Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.

06

What researchers measure

Primary outcomes

  1. Device usage (recording time)

    Total recording time per recording period (hours)

    Time frame: Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24

  2. Patient compliance (Min)

    Percentage of participants achieving minimal threshold (expected 50h) of recording time per period

    Time frame: Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24

  3. Patient compliance (Max)

    Percentage of participants achieving optimal threshold (expected 180h) of recording time per period

    Time frame: Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24

Secondary outcomes

  1. Reliability

    Intraclass Correlation Coefficient (ICC) for two distinct consecutive half-periods

    Time frame: Baseline, Month 6, Month 12, Month 18, Month 24

  2. Clinical validity of digital outcome vs Brooke

    Correlation between digital outcome and Brooke Upper Extremity Rating Scale (Brooke score)

    Time frame: Baseline, Month 6, Month 12, Month 18, Month 24

  3. Clinical validity of digital outcome vs PUL

    Correlation between digital outcome and Performance of Upper Limb (PUL) score

    Time frame: Baseline, Month 6, Month 12, Month 18, Month 24

  4. Sensitivity of Digital Upper Limb Outcome Measures

    Sensitivity will be evaluated by assessing the ability of digital outcome measures to detect change over time combining mean change from baseline, slope of change over time, and standardized response mean (SRM).

    Time frame: Baseline, Month 6, Month 12, Month 18, Month 24

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jun 2029, 35 months later.

Of 45 non-industry interventional studies with no phase under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 35 months is above that.

Counting every sponsor, half of 47 studies reached it within 20 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 23, 2026
StartEst.
Jul 30, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Apr 30, 2030
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07664124
Lead sponsor
Centre Hospitalier Universitaire de Liege
Collaborators
Centre Hospitalier Régional de la Citadelle, SYSNAV
Responsible party
Laurent Servais (Principal Investigator, Pediatrician, Centre Hospitalier Universitaire de Liege) — Principal investigator
First posted
Jun 23, 2026
Start date
Jul 30, 2026 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Jun 23, 2026

Study contacts

Dounia Chelha
Contact
Khadidja.Chelha@citadelle.be
+3243215498
Laurent Servais, MD
principal investigator · Centre Hospitalier Universitaire de Liege

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion